Cancer Intervention Surveillance Modeling Network (CISNET)
Modeling Prostate Cancer Control: Prevention, screening, treatment, follow-up care
This study uses models of disease progression informed by observational and trial datasets to learn about the likely outcomes of different prostate cancer management strategies. The models, at FHCRC, Erasmus Medical Center (PI: de Koning) and the University of Michigan (PI: Tsodikov), will be used to conduct “virtual population trials” to inform policymakers about the costs and benefits of candidate screening and treatment strategies for the general population and by patient comorbidity, race, and obesity status. The broad, long-term goal is to position disease modeling as a viable tool for clinical decision making and policy development. Using the three complementary surveillance models developed by the CISNET prostate group we will address some of the most persistent and pressing policy questions in prostate cancer, including the value of PSA screening versus advances in prostate cancer treatment,
and the link between disparities in care and racial differences in
prostate cancer outcomes. Dr. Etzioni is the PI of the Coordinating Center for this award. This activity is supported by a grant from the National Institute of Health/National Cancer Institute grant (U01 CA157224) and administrative supplement (U01 CA088160-S1).
Publications
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101(6):374–383. PMCID: PMC2720697. Abstract / Full Text
Etzioni R, Gulati R, Mariotto AB. Overview of prostate cancer trends in the era of PSA screening. In: Ankerst DP, Tangen CM, Thompson IM, editors. Prostate Cancer screening. 2nd ed. Humana Press; 2009. p. 3-14.
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R. Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev 2009 Mar;18(3):808-15. PMCID: PMC2750884. Abstract / Full Text
Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol 2008 May;9(5):407-9.
Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on
the incidence of advanced stage prostate cancer in the US: A
surveillance modeling approach. Medical Decision Making. 2008 Mar 4;28:323-331. Abstract / Full Text
Inoue LYT, Etzioni R, Morrell C, Müller P. Modeling Disease Progression with Longitudinal Markers. Journal of the American Statistical Association. 2008 Mar;103(481):259-270. Abstract
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, diTommaso D, Karnofski K, Gulati R, Penson DFG, Feuer EJ. Quantifying the Role of PSA Screening in the US Prostate Cancer Mortality Decline. Cancer Causes and Control. 2008 Mar;19(2):175-81. Abstract / Full Text
Telesca D, Gulati R, Etzioni R. Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends. Biometrics. 2008 Mar;64(1):10-9. Abstract / Full Text
Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007 Mar 19;109(9):1877-1886. Abstract / Full Text
Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2006 Oct 1;66(2):395-402. Abstract / Full Text
Shaw PA, Etzioni R, Zeliadt SB, Mariotto M, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An Ecologic Study of PSA Screening and Prostate Cancer Mortality in Nine Geographic Areas of the US. American Journal of Epidemiology. 2004 Dec 1;160(11):1059-69. Abstract / Full Text
Feuer EJ, Etzioni R, Cronin K, Mariotto A. The Use of Modeling to Understand the Impact of Screening on US Mortality: Examples from Mammography and PSA Testing. Statistical Methods in Medical Research. 2004 Dec; 13(6) 421-42. Abstract
Inoue L, Etzioni R, Slate EH, Morrell C. Combining longitudinal studies of PSA. Biostatistics. 2004 Jul;5(3): 483-500. Abstract / Full Text
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute 2002 Jul 3;94(13):981-990. Abstract / Full Text
Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute 1999 Jun 16;91(12):1033-1039. Abstract / Full Text
